338 related articles for article (PubMed ID: 34093858)
1. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
2. Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells.
Pfirschke C; Zilionis R; Engblom C; Messemaker M; Zou AE; Rickelt S; Gort-Freitas NA; Lin Y; Bill R; Siwicki M; Gungabeesoon J; Sprachman MM; Marquard AN; Rodell CB; Cuccarese MF; Quintana J; Ahmed MS; Kohler RH; Savova V; Weissleder R; Klein AM; Pittet MJ
Cancer Immunol Res; 2022 Jan; 10(1):40-55. PubMed ID: 34795032
[TBL] [Abstract][Full Text] [Related]
3. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
4. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of CD8
Zhang Y; Gao X; Yan B; Wen N; Lee WSV; Liang XJ; Liu X
ChemMedChem; 2022 Jan; 17(2):e202100656. PubMed ID: 34806311
[TBL] [Abstract][Full Text] [Related]
6. Ferrimagnetic Vortex Nanoring-Mediated Mild Magnetic Hyperthermia Imparts Potent Immunological Effect for Treating Cancer Metastasis.
Liu X; Zheng J; Sun W; Zhao X; Li Y; Gong N; Wang Y; Ma X; Zhang T; Zhao LY; Hou Y; Wu Z; Du Y; Fan H; Tian J; Liang XJ
ACS Nano; 2019 Aug; 13(8):8811-8825. PubMed ID: 31328922
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract][Full Text] [Related]
8. Rh-CSF1 Attenuates Oxidative Stress and Neuronal Apoptosis via the CSF1R/PLCG2/PKA/UCP2 Signaling Pathway in a Rat Model of Neonatal HIE.
Hu X; Li S; Doycheva DM; Huang L; Lenahan C; Liu R; Huang J; Gao L; Tang J; Zuo G; Zhang JH
Oxid Med Cell Longev; 2020; 2020():6801587. PubMed ID: 33101590
[TBL] [Abstract][Full Text] [Related]
9. Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12.
Jiang X; Cao G; Gao G; Wang W; Zhao J; Gao C
J Cell Physiol; 2021 Jan; 236(1):193-204. PubMed ID: 32495392
[TBL] [Abstract][Full Text] [Related]
10. Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.
Beckmann N; Giorgetti E; Neuhaus A; Zurbruegg S; Accart N; Smith P; Perdoux J; Perrot L; Nash M; Desrayaud S; Wipfli P; Frieauff W; Shimshek DR
Acta Neuropathol Commun; 2018 Feb; 6(1):9. PubMed ID: 29448957
[TBL] [Abstract][Full Text] [Related]
11. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
12. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
14. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
Wang Y; Luan Z; Zhao C; Bai C; Yang K
Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
[TBL] [Abstract][Full Text] [Related]
15. Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer.
Lu X; Meng T
Immunobiology; 2019 May; 224(3):355-361. PubMed ID: 30926154
[TBL] [Abstract][Full Text] [Related]
16. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.
Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D
Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
20. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
